title: New drugs in prostate cancer.
abstract: The standard primary treatment for advanced prostate cancer has been hormonal therapy since the 1940s. However, prostate cancer inevitably progresses to castration-resistant prostate cancer (CRPC) after a median duration of 18 months of androgen deprivation therapy. In patients with CRPC, docetaxel has been regarded as the standard treatment. However, survival advantages of docetaxel over other treatments are slim, and the need for new agents persists. In recent years, novel agents, including abiraterone, enzalutamide, cabazitaxel, radium-223, and sipuleucel-T, have been approved for the treatment of CRPC, and more such agents based on diverse mechanisms are under investigation or evaluation. In this article, the authors reviewed the current literature on recent advances in medical treatment of prostate cancer, especially CRPC. In addition, the authors elaborated on novel drugs for prostate cancer currently undergoing investigation and their mechanisms.
authors.affiliation: Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
authors.forename: Sangjun
authors.initials: S
authors.lastname: Yoo
authors.affiliation: Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
authors.forename: Se Young
authors.initials: SY
authors.lastname: Choi
authors.affiliation: Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
authors.forename: Dalsan
authors.initials: D
authors.lastname: You
authors.affiliation: Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
authors.forename: Choung-Soo
authors.initials: CS
authors.lastname: Kim
keywords: Castration Resistant; Drug Therapy; Drugs; Investigational; Prostatic Neoplasm